Judith Margarete Gottwein

• Presentation
• CV
• Research outputs
• Keywords
• Most downloaded

Personal data

Name: Judith Margarete Gottwein; Date of birth: February 24, 1975

Citizenship: German; Country of Residence: Denmark

Address: Helikonsvej 5, 2300 København; Phone: +45 - 24 34 53 35

E-mail: jgottwein@sund.ku.dk or Judith.Margarete.Gottwein@regionh.dk

ORCID: 0000-0003-2805-0256

 

Current employment

1. Sept 2019 – present:

- Professor, CO-HEP, Dep. of Immunology and Microbiology (ISIM), Faculty of Health and Medical Sciences, University of Copenhagen (UCPH), Denmark

- Afdelingslæge, Copenhagen Hepatitis C Program (CO-HEP), Dep. of Infectious Diseases, Copenhagen University Hospital, Hvidovre (HVH), Denmark

 

Education

1. Feb 2005:

License to Practice and License to Practice Independently as a Medical Doctor in Denmark

1. Nov 2003:

License to Practice Independently as a Medical Doctor in Germany

1. Dec 2001:

Doctoral Degree (Dr. med.), Heidelberg University

1. Nov 2001:

Medical Doctor Degree (MD), Heidelberg University

1994-2001:

Studies of Medicine, Heidelberg University

1997-1998:

1 year research in immunology and vaccinology, Dep. of Pathology, Case Western Reserve University, Cleveland, Ohio, USA. Experimental work for doctoral thesis.

 

Employment history

1. Sept 2014 - 31. Aug 2019:

Associate Professor, CO-HEP, Dep. of Infectious Diseases HVH and ISIM, UCPH, Denmark

1. Sept 2009 - 31. Aug 2014:

Senior Researcher, CO-HEP, Dep. of Infectious Diseases, HVH, Denmark

1. Sept 2005 - 31. Aug 2009:

Ph.D. equivalent, CO-HEP, Dep. of Infectious Diseases, HVH, Denmark

1. Jan 2005 - 31. Aug 2005:

Clinician and Research Fellow, Dep. of Internal Medicine I, University Hospital Bonn, Germany

1. Feb 2003 - 31. Aug 2004:

Clinician, Dep. of Internal Medicine, Spital Limmattal, Schlieren, Switzerland

1. Jan 2002 - 31. Jan 2003:

Research Fellow and Clinician, Dep. of Neuropathology, University Hospital Zürich, Switzerland

 

Scientific focus areas

-Translational studies in virology, focusing on hepatitis C virus and severe acute respiratory system coronavirus 2

-Development of whole virus inactivated vaccines and studies of neutralizing antibodies

-Development of cell culture systems for study of viruses

-Study of antivirals and antiviral resistance

 

Brief outline of key research contributions

My research focuses on basic and translational studies in virology. While my long-term research focus is hepatitis C virus (HCV), more recent work has also focused on severe acute respiratory system coronavirus 2 (SARS-CoV-2). On an international level, I was the first to develop molecular clones of HCV genotypes 3 to 6 and I have pioneered development of infectious HCV cell culture systems for the major genotypes. I have used these systems for studies of various antivirals, their mechanism of action and associated resistance. Further, my research has revealed that different HCV variants show differential sensitivity to neutralizing antibodies, indicating existence of various HCV serotypes, but also that immunization with an envelope subunit vaccine was able to induce cross-genotype neutralizing antibodies. I have contributed to important functional studies on HCV entry and studies on the function of specific HCV genome regions and proteins. Ongoing research has contributed breakthrough findings for development of a whole virus inactivated HCV vaccine. Research on SARS-CoV-2 has focussed on identification of antivirals with efficacy against this virus and development of a whole virus inactivated vaccine.

 

Scientific qualifications and academic awards and honours

- Presentations at scientific meetings including invited presentations: EASL Annual Meeting: 2014, 2013, 2009, 2007. International Symposium on Hepatitis C Virus and Related Viruses: 2022, 2021, 2019, 2018, 2017, 2015, 2012, 2011, 2010, 2009, 2008, 2007. ESACT Annual Meeting: 2019, 2017. HIV and Hepatitis Nordic Conference: 2017. Viruses: 2020.

-Ad hoc reviewer for Antimicrobial Agents and Chemotherapy, Antiviral Research, Biotech Journal, Clinical Microbiology, Hepatology, Journal of Viral Hepatitis, Science, Scientific Reports, Viruses.

-Involvement in PhD evaluations as opponent (2) and chair (1).

-Prizes from EASL (2007 and 2009) and the International Symposium on Hepatitis C Virus and Related Viruses (2007, 2008, 2010).

-Fellowship of the German Academic Scholarship Foundation: 1994-2001.

 

Management experience

-Since 2005: Establishment of research facilities at CO-HEP, developing from 3 to +50 members

-Since 2009: Main responsibilities for project management, including main responsibility for a number of research projects with focus on translational virology, for example funded by Innovation Fund Denmark (Innoexplorer grant): 2021-2022; 2019-2020; Independent Research Foundation Denmark: 2020-2023 and 2013-2016, The Carlsberg foundation (2022), The Novo Nordisk Foundation Pre-Seed Grant (2017-2019), Læge Sophus Carl Emil Friis og hustru Olga Doris Friis ́ Legat: 2018-2020.

 

Teaching activities

-Virology Lectures and practical exercises for 3^rd year Medical students on BSc level – Mikrobiologisk Øvelseskursus, UCPH

-Virology Lectures for 1^st year Human Biology students on MSc level – Immunology and Microbiology, UCPH

-Lectures for young medical doctors, nurses and students – Dept. of Infectious Diseases, HVH

 

Research grants received last 5 years

Hvidovre Hospital Research Foundation: 2021

Innovation Fund Denmark (Innoexplorer grant): 2021-2022; 2019-2020

Region Hovedstadens Forskningsfond (co-written Jens Bukh): 2019-2021

Independent Research Foundation, Denmark: 2020-2023

The Carlsberg Foundation: 2022

The Novo Nordisk Foundation: Pre-Seed Grant (co-written Jens Bukh): 2017-2019

The Toyota Foundation: 2018

Læge Sophus Carl Emil Friis og hustru Olga Doris Friis ́ Legat: 2018-2020

 

International relations

Genzel, Marichal-Gallardo and Reichl, Max Planck Institute Magdeburg, Germany; Grzyb, University of Gdańsk, Poland; J. Law, University of Alberta; M. Law, The Scripps Research Institute, USA; Lehmann, Case Western Reserve University, Cleveland, USA; Meuleman, Ghent University, Belgium; Pawlotsky, Henri Mondor University Hospital, Créteil, France; Rice, The Rockefeller University, USA; Sarrazin, University Hospital Frankfurt, Germany; Wolff, Technische Hochschule Mittelhessen, Germany; Xiangliang Lin, Esco Aster, Singapore.

 

National collaborations

Krarup, Aalborg University; Benfield and Weiss, Copenhagen University Hospital; Pedersen, SSI; Pravsgaard Christensen, UCPH

 

Supervision

- Master students: 2007-2020: T. Jensen, S. Jensen, Pihl, Alzua, Offersgaard, Gammeltoft, Hernandez. All grade 12 (best possible grade).

- Ph.D. students: thesis 2014-2020: T. Jensen, Mathiesen, Serre, S. Jensen, Vélazquez-Moctezuma, Pham, Pihl, Alzua. Ongoing: Offersgaard, Antúnez, Zhou, Gammeltoft, Hernandez, Zhe.

- Postdoctoral fellows: 2014-2019: T. Jensen, Mathiesen, Serre. Ongoing: Feng, Pihl, Alzua

 

Languages

German, English, Danish

 

Publication summary

-63 peer-reviewed publications, 57 with impact factor (IF) ≥5; 22 with IF ≥10; 12 with IF ≥30;

15 first and 17 corresponding authorships

-citations +4200, H-index 34 (google scholar, October 2022)

-Book chapters: 2

-Patents: 16 issued (6 as first and 1 as senior author). 3 applications. HCV culture systems licensed to Apath, USA

 

Peer-reviewed manuscripts

Impact factor. 2022 Journal Citation Reports

1. Gottwein JM, Blanchard TG, Targoni OS, Eisenberg JC, Zagorski BM, Redline RW, Nedrud JG, Tary-Lehmann M, Lehmann PV, Czinn SJ. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis. 2001; 184, 308-14. Impact Factor: 7.8

2. Rogivue C, Gottwein J, Aguzzi A, Glatzel M. Transmissible spongiform encephalopathies in humans. Schweizer Archiv Für Tierheilkunde 2002; 144, 685-90. Impact Factor: 0.9

3. Glatzel M, Gottwein J, Aguzzi A. The role of prions in transmissible spongiform encephalopathies. Schweizer Archiv Für Tierheilkunde 2002; 144, 633-8. Impact Factor: 0.9

4. Eisenberg JC, Czinn SJ, Garhart CA, Redline RW, Bartholomae WC, Gottwein JM, Nedrud JG, Emancipator SE, Boehm BB, Lehmann, PV, Blanchard TG. Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice. Infection and Immunity 2003; 71, 1820-7. Impact Factor: 3.4

5. Gottwein J, Wiesli P, Achermann E. Thyroid storm as first manifestation of hyperthyroidism. Swiss Medical Weekly 2005, 37, 933-5. Impact Factor: 2.2

6. Gottwein J, Zbinden R, Maibach RC, Herren T. Etiologic diagnosis of Capnocytophaga canimorsus meningitis by broad-range PCR. European Journal of Clinical Microbiology & Infectious Diseases 2006; 25, 132-4. Impact Factor: 3.3

7. Gottwein JM, Bukh J. Hepatitis C virus host cell interactions uncovered. Proc Natl Acad Sci USA 2007; 104: 13215-6. Impact Factor: 11.2

8. Gottwein JM, Scheel TKH, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G, Bukh J. Robust Hepatitis C Genotype 3a Cell Culture Releasing Adapted Intergenotypic 3a/2a (S52/JFH1) Viruses. Gastroenterology 2007; 133: 1614-26. Impact Factor: 33.9

9. Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen-Olsen J, Bukh J. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci USA 2008; 105: 997-1002. Impact Factor: 11.2

10. Gottwein JM, Bukh J. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv Virus Res. 2008; 71: 51-133. Impact Factor: 9.9

11. Jensen TB, Gottwein JM, Scheel TKH, Hoegh AM, Eugen-Olsen J, Bukh J. Highly efficient JFH1-based cell culture system of hepatitis C virus genotype 5a: failure to control infection with homologous neutralizing antibody treatment. J Infect Dis. 2008; 198: 1756 –65. Impact Factor: 7.8

12. Gottwein JM, Scheel TKH, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J. Development and Characterization of Hepatitis C Virus Genotype 1-7 Cell Culture Systems: Role of CD81 and SR-BI and Effect of Antiviral Drugs. Hepatology 2009; 49: 364-77. Impact Factor: 17.4

13. Terjung B, Soehne J, Lechtenberg B, Gottwein J, Muennich M, Herzog V, Maehler M, Sauerbruch T, Spengler U. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010; 59: 712-3. Impact Factor: 31.8

14. Gottwein JM*, Scheel TK*, Callendret B, Li YP, Eccleston HB, Engle RE, Govindarajan S, Satterfield W, Purcell RH, Walker CM, Bukh J. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol. 2010; 84: 5277-93. * authors contributed equally. Impact Factor: 6.6

15. Scheel TKH*, Gottwein JM*, Mikkelsen M, Jensen TB, Bukh J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology 2011; 140: 1032-42. * authors contributed equally. Impact Factor: 33.9

16. Prentoe JC, Jensen TB, Meuleman P, Serre S, Scheel TKH, Leroux-Roels G, Gottwein JM, Bukh J. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol. 2011; 85: 2224-34. Impact Factor: 6.6

17. Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U, Weis N, Bukh J. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. J Virol. 2011; 85: 2891-906. Impact Factor: 6.6

18. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci USA 2011; 108: 4991-6. Impact Factor: 11.2

19. Gottwein JM, Jensen TB, Mathiesen CK, Meuleman P, Serre SB, Lademann JB, Ghanem L, Scheel TK, Leroux-Roels G, Bukh J. Development and Application of Hepatitis C Reporter Viruses with Genotype 1-7 Core-NS2 Expressing Fluorescent Proteins or Luciferase in modified JFH1 NS5A. J Virol. 2011; 85: 8913-28. Impact Factor: 6.6

20. Gottwein JM*, Scheel TK*, Jensen TB, Ghanem L, Bukh J. Differential Efficacy of Protease Inhibitors against HCV Genotype 2a, 3a, 5a, and 6a NS3/4A Protease Recombinant Viruses. Gastroenterology 2011; 141: 1067-79. * authors contributed equally. Impact Factor: 33.9

21. Meunier JC, Gottwein JM, Houghton M, Russell R, Houghton M, Emerson SU, Houghton M, Bukh J, Purcell RH. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis. 2011; 204: 1186-90. Impact Factor: 7.8

22. Li YP, Ramirez S, Gottwein JM, Bukh J. Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon. Virology 2011; 421: 222-34. Impact Factor: 5.1

23. Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L, Purcell RH, Bukh J. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc Natl Acad Sci USA 2012; 109: E1101-10. Impact Factor: 11.2

24. Scheel TK, Prentoe J, Carlsen TH, Mikkelsen LS, Gottwein JM, Bukh J. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems. PLoS Pathog. 2012; 8: e1002696. Impact Factor: 7.5

25. Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM. Efficient replication of genotype 3a and 4a HCV replicons in human hepatoma cells. Antimicrob Agents Chemother. 2012; 56: 5365-73. Impact Factor: 5.9

26. Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM, Bukh J. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad Sci USA 2012; 109: 19757-62. Impact Factor: 11.2

27. Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J. Combination treatment with HCV protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a and 3a virus. Antimicrob Agents Chemother. 2013; 57: 1291-303. Impact Factor: 5.9

28. Scheel TK, Galli A, Li YP, Mikkelsen LS, Gottwein JM, Bukh J. Productive Homologous and Non-homologous Recombination of Hepatitis C Virus in Cell Culture. PLoS Pathog. 2013: 9:e1003228. Impact Factor: 7.5

29. Pedersen J, Carlsen TH, Prentoe J, Ramirez S, Jensen TB, Forns X, Alter H, Foung SK, Law M, Gottwein J, Weis N, Bukh J. Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. Hepatology 2013; 58: 1587-97. Impact Factor: 17.4

30. Gottwein JM, Bukh J. Viral hepatitis: Cell-culture-derived HCV-a promising vaccine antigen. Nat Rev Gastroenterol Hepatol. 2013; 10: 508-9. Impact Factor: 73.1

31. Galli A, Scheel TK, Prentoe JC, Mikkelsen LS, Gottwein JM, Bukh J. Analysis of hepatitis C virus Core/NS5A co-localization using novel cell culture systems expressing Core-NS2 and NS5A of genotype 1-7. J Gen Virol. 2013; 94: 2221-35. Impact Factor: 5.1

32. Gottwein JM, Jensen SB, Serre SBN, Ghanem L, Scheel TKH, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J. Adapted J6/JFH1-based hepatitis C virus recombinants with genotype-specific NS4A show similar efficacy to lead protease inhibitors, interferon-alpha and a putative NS4A inhibitor. Antimicrob Agents Chemother. 2013; 57: 6034-49. Impact Factor: 5.9

33. Serre SBN, Krarup H, Bukh J, Gottwein JM. Identification of IFN-alpha Induced Envelope Mutations of Hepatitis C Virus In Vitro Associated with Increased Viral Fitness and Interferon Resistance. J Virol. 2013; 87: 12776-93. Impact Factor: 6.6

34. Prentoe J, Serre SB, Ramirez S, Nicosia A, Gottwein JM, Bukh J. Hypervariable Region 1 Deletion and Required Adaptive Envelope Mutations Confer Decreased Dependency on Scavenger Receptor Class B Type I and Low Density Lipoprotein Receptor for Hepatitis C Virus. J Virol. 2013; 88: 1725-39. Impact Factor: 6.6

35. Ramirez S, Li YP, Jensen SB, Pedersen J, Gottwein JM, Bukh J. Highly efficient infectious cell culture of three HCV genotype 2b strains and sensitivity to lead protease, NS5A, and polymerase inhibitors. Hepatology 2014; 59: 395-407. Impact Factor: 17.4

36. Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J. Differential Sensitivity of 5'UTR-NS5A Recombinants of Hepatitis C Virus Genotypes 1-6 to Protease and NS5A Inhibitors. Gastroenterology 2014; 146: 812-821. Impact Factor: 33.9

37. Mathiesen CK, Jensen TB, Prentoe J, Nicosia A, Law M, Bukh J, Gottwein JM. Production and Characterization of High-Titer Serum-Free Cell Culture Grown Hepatitis C Virus Particles of Genotype 1-6. Virology 2014; 458-459: 190-208. Impact Factor: 5.1

38. Sundararaman S, Karulin AY, Ansari T, BenHamouda N, Gottwein J, Laxmanan S, Levine SM, Loffredo JT, McArdle S, Neudoerfl C, Roen D, Silina K, Welch M, Lehmann PV. High Reproducibility of ELISPOT Counts from Nine Different Laboratories. Cells 2015; 4: 21-39. Impact Factor: 7.7

39. Mathiesen CK, Prentoe J, Meredith LW, Jensen TB, Krarup H, McKeating JA, Gottwein JM, Bukh J. Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant. J Virol. 2015; 89: 7758-75. Impact Factor: 6.6

40. Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM. Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance. Antimicrob Agents Chemother. 2015; 59: 7426-36. Impact Factor: 5.9

41. Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. Antimicrob Agents Chemother. 2016; 60: 3563-78. Impact Factor: 5.9

42. Ramirez S, Mikkelsen LS, Gottwein JM, Bukh J. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir. Gastroenterology. 2016; 151: 973-985. Impact Factor: 33.9

43. Pham LV, Ramirez S, Carlsen THR, Li YP, Gottwein JM, Bukh J. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors. Antimicrob Agents Chemother. 2017; 61: e00037-17. Impact Factor: 5.9

44. Gottwein JM*, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Bukh J*. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants. Gastroenterology. 2018; 154: 1435-48. *corresponding author. Impact Factor: 33.9

45. Pham LV, Ramirez S, Gottwein JM, Fahnøe U, Li YP, Pedersen J, Bukh J. HCV Genotype 6a Escape from and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. Gastroenterology. 2018; 154: 2194-208. Impact Factor: 33.9

46. Galli A, Mens H, Gottwein JM, Gerstoft J, Bukh J. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model. Sci Rep. 2018; 8: 4619. Impact Factor: 5.0

47. Humes D, Ramirez S, Jensen TB, Li YP, Gottwein JM, Bukh J. Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. Virology. 2018; 522: 177-92. Impact Factor: 5.1

48. Pihl A, Offersgaard AF, Mathiesen CK, Prentoe J, Fahnøe U, Krarup H, Bukh J, Gottwein JM. High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals. Sci Rep. 2018; 8: 17505. Impact Factor: 5.0

49. Pham LV, Jensen SB, Fahnøe U, Pedersen MS, Tang Q, Ghanem L, Ramirez S, Humes D, Serre SBN, Schønning K, Bukh J, Gottwein JM. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape. J Hepatol. 2019; 70: 388-97. Impact Factor: 30.1

50. Jensen SB, Fahnøe U, Pham LV, Serre S, Tang Q, Ghanem L, Pedersen MS, Ramirez S, Humes D, Pihl AF, Filskov J, Sølund CS, Dietz J, Fourati S, Pawlotsky J-M, Sarrazin C, Weis N, Schønning K, Krarup H, Bukh J, Gottwein JM. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology. 2019; 70: 771-787. Impact Factor: 17.4

51. Czarnota A, Offersgaard A, Pihl AF, Prentoe J, Bukh J, Gottwein JM, Bieńkowska-Szewczyk K, Grzyb K. Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. Vaccines. 2020; 8: 294. Impact Factor: 5.0

52. Lothert K, Offersgaard AF, Pihl AF, Mathiesen CK, Jensen TB, Alzua GP, Fahnøe U, Bukh J, Gottwein JM*, Wolff MW*. Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine. Sci Rep. 2020; 10: 16261. * authors contributed equally. Impact Factor: 5.0

53. Ramirez S, Fernandez-Antunez C, Galli A, Underwood A, Pham LV, Ryberg LA, Feng S, Pedersen MS, Mikkelsen LS, Belouzard S, Dubuisson J, Sølund C, Weis N, Gottwein JM, Fahnøe U, Bukh J. Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication. Antimicrob Agents Chemother. 2021; 65: e0009721. Impact Factor: 5.9

54. Gammeltoft KA, Zhou Y, Duarte Hernandez CR, Galli A, Offersgaard A, Costa R, Pham LV, Fahnøe U, Feng S, Scheel TKH, Ramirez S, Bukh J, Gottwein JM. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro. Antimicrob Agents Chemother. 2021; 65: e0268020. Impact Factor: 5.9

55. Offersgaard A, Duarte Hernandez CR, Pihl AF, Costa R, Venkatesan NP, Lin X, Van Pham L, Feng S, Fahnøe U, Scheel TKH, Ramirez S, Reichl U, Bukh J, Genzel Y, Gottwein JM. SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor. Vaccines. 2021; 29:706. Impact Factor: 5.0

56. Zhou Y*, Gilmore K*, Ramirez S, Settels E, Gammeltoft KA, Pham LV, Fahnøe U, Feng S, Offersgaard A, Trimpert J, Bukh J, Osterrieder K, Gottwein JM*, Seeberger PH*. In vitro efficacy of artemisinin-based treatments against SARS-CoV-2. Sci Rep. 2021; 11:14571. * authors contributed equally. Impact Factor: 5.0

57. Prentoe J, Janitzek CM, Velázquez-Moctezuma R, Goksøyr L, Olsen RW, Fanalista M, Augestad EH, Thrane S, Pihl AF, Gottwein JM, Sander AF, Bukh J. Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. PLoS One. 2021; 16:e0255336. Impact Factor: 3.8

58. Zhou Y, Gammeltoft KA, Galli A, Offersgaard A, Fahnøe U, Ramirez S, Bukh J, Gottwein JM. Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for Treatment of SARS-CoV-2 in Vitro. Viruses. 2021; 13:2082. Impact Factor: 5.8

59. Pihl AF, Feng S, Offersgaard A, Alzua GP, Augestad EH, Mathiesen CK, Jensen TB, Krarup H, Law M, Prentoe J, Christensen JP, Bukh J, Gottwein JM. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. J Hepatol. 2022; 76:1051-1061. Impact Factor: 30.1

60. Offersgaard A, Duarte Hernandez CR, Pihl AF, Venkatesan NP, Krarup H, Lin X, Reichl U, Bukh J, Genzel Y, Gottwein JM. High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor. Vaccines. 2022; 10:249. Impact Factor: 5.0

61. Fahnøe U, Pham LV, Fernandez-Antunez C, Costa R, Rivera-Rangel LR, Galli A, Feng S, Mikkelsen LS, Gottwein JM, Scheel TKH, Ramirez S, Bukh J. Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication. Viruses. 2022; 14:172. Impact Factor: 5.8

62. Alzua G, Pihl AF, Offersgaard A, Hernandez CRD, Zhe D, Feng S, Fahnøe U, Sølund C, Weis N, Law M, Prentoe J, Christensen J, Bukh J, Gottwein JM. Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralizing antibodies in mice. Gut. 2022; Aug 2:gutjnl-2021-326323. doi: 10.1136/gutjnl-2021-326323. Online ahead of print. Impact Factor: 31.8

63. Alzua GP, Pihl AF, Offersgaard A, Velázquez-Moctezuma R, Hernandez CRD, Augestad EH, Fahnøe U, Mathiesen CK, Krarup H, Law M, Prentoe J, Bukh J, Gottwein JM. Identification of novel neutralizing determinants for protection against hepatitis C virus. Hepatology. 2022 Sep 3. doi: 10.1002/hep.32772. Online ahead of print. Impact Factor: 17.4

 

Book Chapters

1. Gottwein J, Aguzzi A. Prionenkrankheiten (original von Stanley B. Prusiner und Patrick Bosque). Harrison Innere Medizin. 2002; 15. Auflage. Deutsche Ausgabe. Hrsg. Manfred Dietel, Joachim Dudenhausen, Norbert Suttorp. 2708-2719.

2. Bukh J, Gottwein JM, Scheel TK & Forns X. Hepatitis C: the virus and studies of its lifecycle in cell culture systems. in X Forns (ed.), 100 Key Questions on Hepatitis C. 2008; 1 edn, vol. 1, Permanyer Publications, Barcelona, Spain. 1-15.

 

Patents and Patent Applications:

Issued Patents

1. Efficient cell culture system for hepatitis C virus genotype 2b. Patent #: 8,663,653 (March 04, 2014). Inventors: Gottwein JM, Knudsen ML, Scheel TKH, and Bukh J

2. Efficient cell culture system for hepatitis C virus genotype 5a. Patent #: 8,618,275 (December 31, 2013). Inventors: Jensen TB, Gottwein JM, Scheel TKH, Eugen-Olsen J, and Bukh J

3. Efficient cell culture system for hepatitis C virus genotype 6a. Patent #: 8,569,472 (October 29, 2013). Inventors: Gottwein JM, Scheel TKH, Jensen TB, and Bukh J

4. Efficient cell culture system for hepatitis C virus genotype 1a and 1b. Patent #: 8,563,706 (October 22, 2013). Inventors: Scheel TKH, Prentø J, Gottwein JM, Jensen TB, and Bukh J

5. Efficient cell culture system for hepatitis C virus genotype 7a. Patent #: 8,506,969 (August 13, 2013). Inventors: Gottwein JM, Scheel TKH, Jensen TB, and Bukh J

6. Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4a. Patent #: 8,454,974 (June 4, 2013). Inventors: Scheel TKH, Gottwein JM, Eugen-Olsen J, and Bukh J

7. Infectious genotype 1a, 2a, 3a, 5a and 6a hepatitis C virus lacking the hypervariable region 1 (HVR1). Patent #: 8,846,891 (September 30, 2014). Inventors: Prentø JC, Gottwein JM, Scheel TKH, Jensen TB, and Bukh J

8. Hepatitis C virus expressing reporter tagged NS5A protein. Patent #: 8,772,022 (July 8, 2014). Inventors: Gottwein JM, Lademann JB, Scheel TKH, Jensen TB, Li Y, Prentoe JC, and Bukh J

9. Cell Culture System of a hepatitis C genotype 3a and 2a chimera. Patent #: 8,945,584 (February 3, 2015). Inventors: Gottwein JM, Scheel TKH, Eugen-Olsen J, and Bukh J

10. Infectious Hepatitis C Viruses of Genotype 3a and 4a and Uses thereof. Patent #: 8,946,398 (February 3, 2015). Inventors: Gottwein JM, Scheel TKH, Purcell R, and Bukh

Infectious Hepatitis C Viruses of Genotype 3a and 4a and Uses thereof (Continuation, 3a divisional). U.S. Patent #: 9,683,269 (June 20, 2017). Inventors: Gottwein JM, Scheel TKH, Purcell R, Bukh J

11. JFH-1 based HCV Cell Culture Systems for NS5A of genotype 1-7. Patent #: 9,388,389 (July 12, 2016). Inventors: Scheel TKH, Gottwein JM, Jensen TB, and Bukh J

12. HCV full-length infectious cell culture systems and applications thereof. Patent #: 9,382,517 (July 5, 2016). Inventors: Li YP, Ramirez S, Gottwein JM, Scheel TKH, and Bukh J

13. Robust full-length HCV genotype 2a and 2b infectious culture systems. E.U: Patent #: 2828382 (October 26, 2016). Inventors: Li YP, Ramirez S, Gottwein JM, Scheel TKH, and Bukh J

14. Novel HCV culture systems and direct-acting antiviral sensitivity. Inventors: Li Y, Ramirez S, Humes D, Gottwein J, Bukh J. Patent #: 10,106,783 (October 23, 2018)

15. High-titer HCV full-length genotype 2b infectious cell culture systems and applications thereof. Inventors: Ramirez S, Li YP, Gottwein JM, Bukh J. Patent #: 10,106,872 (October 23, 2018)

16. Development of methods for production of a whole virus vaccine candidate stock and novel adaptive mutations in hepatitis C virus. Inventors: Mathiesen CK, Jensen TB, Bukh J, Gottwein JM. Patent #: 10,258,687 (April 16, 2019)

Filed Patents - not yet issued

1. Efficient cell culture system for hepatitis C virus genotype 6a. Inventors: Pham LV, Ramirez S, Gottwein J, Li YP, Pedersen J, Bukh J

2. Method of purifying whole virus particles. Inventors: Lothert K, Offersgaard A, Pihl A, Bukh J, Gottwein JM, Wolff M

3. High-yield genotype 1a, 2a and 3a HCV. Inventors: Alzua GP, Pihl AF,  Offersgaard A, Fahnøe U, Bukh J, Gottwein JM

Region H/Copenhagen University have licensed the JFH1-based HCV culture systems to Apath, USA (2010 and 2013)